Insulin B (20-30)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596811

CAS#: 91921-56-1

Description: Insulin B (20-30) is a peptide hormone produced by beta cells of the pancreatic islets, and it is considered to be the main anabolic hormone of the body. It regulates the metabolism of carbohydrates, fats and protein by promoting the absorption of, especially glucose from the blood into liver, fat and skeletal muscle cells. In these tissues the absorbed glucose is converted into either glycogen via glycogenesis or fats (triglycerides) via lipogenesis, or, in the case of the liver, into both. Glucose production and secretion by the liver is strongly inhibited by high concentrations of insulin in the blood. Circulating insulin also affects the synthesis of proteins in a wide variety of tissues. It is therefore an anabolic hormone, promoting the conversion of small molecules in the blood into large molecules inside the cells. Low insulin levels in the blood have the opposite effect by promoting widespread catabolism, especially of reserve body fat.

Chemical Structure

Insulin B (20-30)
CAS# 91921-56-1

Theoretical Analysis

MedKoo Cat#: 596811
Name: Insulin B (20-30)
CAS#: 91921-56-1
Chemical Formula: C60H85N15O16
Exact Mass: 1,271.63
Molecular Weight: 1,272.420
Elemental Analysis: C, 56.64; H, 6.73; N, 16.51; O, 20.12

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Insulin B (20-30); Insulin (B20-B30);

IUPAC/Chemical Name: (2R,3S,6S,9S,12S,18S,21S)-3-((S)-2-(((S)-6-amino-1-(((S)-1-carboxyethyl)amino)-1-oxohexan-2-yl)carbamoyl)pyrrolidine-1-carbonyl)-21-(2-aminoacetamido)-9,12-dibenzyl-18-(3-guanidinopropyl)-2-hydroxy-6-(4-hydroxybenzyl)-5,8,11,14,17,20-hexaoxo-4,7,10,13,16,19-hexaazatetracosan-24-oic acid


InChi Code: InChI=1S/C60H85N15O16/c1-34(59(90)91)67-52(83)41(17-9-10-26-61)71-57(88)46-19-12-28-75(46)58(89)50(35(2)76)74-56(87)45(31-38-20-22-39(77)23-21-38)73-55(86)44(30-37-15-7-4-8-16-37)72-54(85)43(29-36-13-5-3-6-14-36)69-48(79)33-66-51(82)40(18-11-27-65-60(63)64)70-53(84)42(24-25-49(80)81)68-47(78)32-62/h3-8,13-16,20-23,34-35,40-46,50,76-77H,9-12,17-19,24-33,61-62H2,1-2H3,(H,66,82)(H,67,83)(H,68,78)(H,69,79)(H,70,84)(H,71,88)(H,72,85)(H,73,86)(H,74,87)(H,80,81)(H,90,91)(H4,63,64,65)/t34-,35+,40-,41-,42-,43-,44-,45-,46-,50-/m0/s1

SMILES Code: C[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H]1N(C([C@H]([C@H](O)C)NC([C@H](CC2=CC=C(O)C=C2)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC4=CC=CC=C4)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CCC(O)=O)NC(CN)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,272.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Guo F, Huang D, Zhang W, Yan Q, Yang Q, Yang Y, Li H, Yun J, Hong W, Yang G. Star-shaped polyester-based elastomers as an implantable delivery system for insulin: Development, pharmacokinetics, pharmacodynamics, and biocompatibility. Mater Sci Eng C Mater Biol Appl. 2018 Mar 1;84:180-187. doi: 10.1016/j.msec.2017.11.045. Epub 2017 Dec 2. PubMed PMID: 29519427.

2: Meriga B, Parim B, Chunduri VR, Naik RR, Nemani H, Suresh P, Ganapathy S, Vvu SB. Antiobesity potential of Piperonal: promising modulation of body composition, lipid profiles and obesogenic marker expression in HFD-induced obese rats. Nutr Metab (Lond). 2017 Nov 16;14:72. doi: 10.1186/s12986-017-0228-9. eCollection 2017. Erratum in: Nutr Metab (Lond). 2017 Dec 6;14 :76. PubMed PMID: 29176994; PubMed Central PMCID: PMC5693419.

3: Gasbjerg LS, Christensen MB, Hartmann B, Lanng AR, Sparre-Ulrich AH, Gabe MBN, Dela F, Vilsbøll T, Holst JJ, Rosenkilde MM, Knop FK. GIP(3-30)NH(2) is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia. 2018 Feb;61(2):413-423. doi: 10.1007/s00125-017-4447-4. Epub 2017 Sep 25. PubMed PMID: 28948296.

4: Fedewa MV, Hathaway ED, Higgins S, Forehand RL, Schmidt MD, Evans EM. Moderate, but not vigorous, intensity exercise training reduces C-reactive protein. Acta Cardiol. 2017 Aug 28:1-8. doi: 10.1080/00015385.2017.1364832. [Epub ahead of print] PubMed PMID: 28847205.

5: El-Far YM, Zakaria MM, Gabr MM, El Gayar AM, El-Sherbiny IM, Eissa LA. A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes. Nanomedicine (Lond). 2016 Oct;11(19):2581-602. doi: 10.2217/nnm-2016-0204. Epub 2016 Sep 13. PubMed PMID: 27623396.

6: Campi I, Vannucchi G, Salvi M. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy. Eur J Endocrinol. 2016 Sep;175(3):R117-33. doi: 10.1530/EJE-15-1164. Epub 2016 Mar 31. Review. PubMed PMID: 27032693.

7: Zhao HQ, Yao G, Yannaing S, ThanThan S, Kuwayama H. Insulinotropic action of bombesin-like peptides mediated by gastrin-releasing peptide receptors in steers. J Anim Sci. 2016 Jan;94(1):58-64. doi: 10.2527/jas.2015-9495. PubMed PMID: 26812312.

8: Bolhassani A, Khavari A, Bathaie SZ. Saffron and natural carotenoids: Biochemical activities and anti-tumor effects. Biochim Biophys Acta. 2014 Jan;1845(1):20-30. doi: 10.1016/j.bbcan.2013.11.001. Epub 2013 Nov 21. Review. PubMed PMID: 24269582.

9: Alexiadou K, Kokkinos A, Liatis S, Perrea D, Katsilambros N, Tentolouris N. Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration. Hormones (Athens). 2012 Oct-Dec;11(4):444-50. PubMed PMID: 23422767.

10: Miki T, Lee KY, Yokoyama T, Liu JQ, Kusaka T, Suzuki S, Ohta K, Warita K, Jamal M, Ueki M, Yakura T, Hosomi N, Takeuchi Y. Differential effects of neonatal maternal separation on the expression of neurotrophic factors in rat brain. II: Regional differences in the cerebellum versus the cerebral cortex. Okajimas Folia Anat Jpn. 2013;90(3):53-8. PubMed PMID: 24670490.

11: Kacso IM, Bondor CI, Kacso G. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Clin Biochem. 2012 Nov;45(16-17):1415-20. doi: 10.1016/j.clinbiochem.2012.07.098. Epub 2012 Jul 23. PubMed PMID: 22836100.

12: Wilson RD, Islam MS. Fructose-fed streptozotocin-injected rat: an alternative model for type 2 diabetes. Pharmacol Rep. 2012;64(1):129-39. PubMed PMID: 22580529.

13: Koricanac G, Tepavcevic S, Zakula Z, Milosavljevic T, Stojiljkovic M, Isenovic ER. Interference between insulin and estradiol signaling pathways in the regulation of cardiac eNOS and Na(+)/K(+)-ATPase. Eur J Pharmacol. 2011 Mar 25;655(1-3):23-30. doi: 10.1016/j.ejphar.2011.01.016. Epub 2011 Jan 25. PubMed PMID: 21272573.

14: Campos-Cornejo F, Campos-Delgado DU, Espinoza-Trejo D, Zisser H, Jovanovic L, Doyle FJ 3rd, Dassau E. An advisory protocol for rapid- and slow-acting insulin therapy based on a run-to-run methodology. Diabetes Technol Ther. 2010 Jul;12(7):555-65. doi: 10.1089/dia.2009.0173. Erratum in: Diabetes Technol Ther. 2010 Sep;12(9):747. PubMed PMID: 20597831.

15: Parkash J. Inflammatory cytokine signaling in insulin producing beta-cells enhances the colocalization correlation coefficient between L-type voltage-dependent calcium channel and calcium-sensing receptor. Int J Mol Med. 2008 Aug;22(2):155-63. PubMed PMID: 18636168.

16: Ennis K, Tran PV, Seaquist ER, Rao R. Postnatal age influences hypoglycemia-induced neuronal injury in the rat brain. Brain Res. 2008 Aug 11;1224:119-26. doi: 10.1016/j.brainres.2008.06.003. Epub 2008 Jun 10. PubMed PMID: 18582442; PubMed Central PMCID: PMC2584018.

17: Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12. PubMed PMID: 18476982.

18: Varma S, Shrivastav A, Changela S, Khandelwal RL. Long-term effects of rapamycin treatment on insulin mediated phosphorylation of Akt/PKB and glycogen synthase activity. Exp Cell Res. 2008 Apr 1;314(6):1281-91. doi: 10.1016/j.yexcr.2007.12.019. Epub 2008 Jan 5. PubMed PMID: 18261725.

19: Kuang HY, Zou W, Zhang GB, Gao XY, Yin HQ. [The relationship of blood glucose and the expression of insulin-like growth factor-1 receptor mRNA in diabetic cardiomyopathy: a preliminary study with rats]. Zhonghua Yi Xue Za Zhi. 2007 May 15;87(18):1249-51. Chinese. PubMed PMID: 17686258.

20: Lindegaard B, Frøsig C, Petersen AM, Plomgaard P, Ditlevsen S, Mittendorfer B, Van Hall G, Wojtaszewski JF, Pedersen BK. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy. Diabetes. 2007 Aug;56(8):2070-7. Epub 2007 Jun 29. PubMed PMID: 17601993.